Kura Sushi to Reproduce Representative Dishes of 70 Countries and Regions Participating in the Osaka-Kansai Expo!
12.12.2024 02:00:00 CET | Business Wire | Press release
70 Expo Special Menu Items UnveiledAntibacterial Sushi Covers with Expo-specific Designs Also Available
Kura Sushi Inc. (Headquarters: Sakai City, Osaka Prefecture), one of the world’s most popular conveyor-belt sushi chains, announced on December 12 that it will offer 70 new menu items at its restaurant that will open at the “Osaka-Kansai Expo,” which will open on April 13 next year in Yumeshima, Osaka, featuring dishes representing 70 countries and regions scheduled to participate in the Expo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211605079/en/
Antibacterial Sushi Covers with Expo-specific Designs (Photo: Business Wire)
The company is the only major revolving sushi chain in Japan to serve sushi on conveyor belts at all of its restaurants. Under the concept of “Revolving Belts Unite the World,” the company will open a restaurant at the Osaka-Kansai Expo with 338 seats, the most in the company’s history, and a revolving belt about 135 meters long, the longest in the company’s history.
With the intention to bring smiles to the faces of visitors from all over the world and provide them with an enjoyable dining experience, the “Hands・Hands Project,” a project that will offer a special 70 Expo menu representing each country and region scheduled to participate in the Expo, will be launched. The menu has been developed by the company’s product development team. The company’s product development team have been working on these menu items with a focus on reproducing the authentic flavors of the countries and regions. Twenty-four of the items have been recreated after being tasted and advised on by ambassadors and other people from these countries under the collaboration with each embassy.
In addition, the antibacterial sushi cover “Mr. Freshness,” which is being used for this special menu, has been specially designed with the connecting part appearing as red and blue hands shaking, the signature colors of the Expo. By serving the special menu side by side with the company’s popular sushi menu, sushi and dishes from different countries and regions flow hand in hand in front of the customers. Along with enjoying their meal, guests will be able to enjoy the experience as if they were visiting a pavilion that explores the culinary cultures of countries around the world.
To help building momentum for the Expo, special Expo menus will be offered ahead of time at about 550 restaurants nationwide, starting on February 7, 2025 (Friday). Each store will offer one item from a menu of 70 different items, as if each store were a “mini-pavilion” where visitors can enjoy the flavors of the respective country. As every neighborhood store will offer a different menu item from a different country or region, customers will be able to enjoy the menu at their local Kura Sushi restaurants, or they can enjoy all 70 items on the Expo special menu by visiting different Kura Sushi restaurants in Japan.
Kaitenzushi (Revolving Sushi Restaurant) is said to have spread throughout Japan after attracting attention at the Osaka Expo in 1970. Since then, Kaitenzushi has steadily expanded its market size while evolving in various ways over its 50-year history, and is now a leading business category in the evolution of the Japanese food service industry, with sales exceeding 800 billion yen. Going forward, the company will continue to leverage its strength, the revolving belt, to provide customers in Japan and overseas with the memorable enjoyment that only Kura Sushi can offer, thereby expanding the revolving sushi business model, a wonderful business model that originated in Japan, to the entire world.
Mr. Makoto Tanaka, Executive Vice President of Kura Sushi, held a press conference on the day of the event, and mentioned, “These days, the world is filled with a variety of social issues that are difficult to solve. Even under such circumstances, we hope that the conveyor-belt sushi restaurants, which are connected by a “conveyor belt that has no beginning and no end,” will unite people from all over the world who visit the Expo to have an enjoyable dining experience with a smile on their faces. We hope that visitors from all over the world, including Japanese customers, as well as tourists from all over the world, will enjoy the menu which we have created with the combined efforts of our Product Development Division to recreate the authentic flavors of the world.”
As of the end of November, Kura Sushi Inc. operates 547 restaurants in Japan, 70 in the United States, 59 in Taiwan, and 3 in Shanghai.
Check out our other products here. https://www.kurasushi.co.jp/2025expo/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211605079/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom